Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Sareum Holdings

    MCap

    GBP35m

    Last close

    GBP0.34

    ▲ 10.25 (44.09%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    VolitionRx

    MCap

    USD70m

    Last close

    USD0.85

    ▲ 0.25 (41.67%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

BiomX – executive interview

BiomX – executive interview

BiomX (NYSE: PHGE) is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectal cancer (CRC), as well as bacteria that affect the appearance of the skin. Phage is a form of virus which attacks only bacteria. BiomX discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.

In our Israel office, EdisonTV interviews BiomX chief executive officer, Jonathan Solomon, providing us with an introduction to the company and an update on its progress.

< Previous
Next >

You may also be interested in these:

Investment Companies

International Public Partnerships - executive interview

Unlocking US capital: Strategies for non-US-listed businesses

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free